AFIB - Acutus Medical, Inc. Stock Price, Fair Value and News

0.06USD+0.01 (+20.00%)Market Closed

Market Summary

USD0.06+0.01

Market Closed

20.00%

AFIB Stock Price

View Fullscreen

AFIB RSI Chart

AFIB Valuation

Market Cap

1.8M

Price/Earnings (Trailing)

-0.03

Price/Sales (Trailing)

0.25

EV/EBITDA

1.92

Price/Free Cashflow

-0.03

AFIB Price/Sales (Trailing)

AFIB Profitability

EBT Margin

33.53%

Return on Equity

1.7K%

Return on Assets

-160.72%

Free Cashflow Yield

-3.6K%

AFIB Fundamentals

AFIB Revenue

Revenue (TTM)

7.2M

Rev. Growth (Yr)

-13.07%

Rev. Growth (Qtr)

-18.2%

AFIB Earnings

Earnings (TTM)

-67.0M

Earnings Growth (Yr)

90.07%

Earnings Growth (Qtr)

95.2%

Breaking Down AFIB Revenue

Last 7 days

50%

Last 30 days

-62.5%

Last 90 days

-70%

Trailing 12 Months

-93.2%

How does AFIB drawdown profile look like?

AFIB Financial Health

Current Ratio

3.48

Debt/Equity

-8.16

Debt/Cashflow

-1.94

AFIB Investor Care

Shares Dilution (1Y)

2.57%

Diluted EPS (TTM)

-2.3

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	4.1M	5.1M	6.1M	7.2M
2022	17.4M	16.7M	15.8M	3.0M
2021	10.5M	14.0M	15.5M	17.3M
2020	4.2M	5.7M	7.1M	8.5M
2019	0	0	0	2.8M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Acutus Medical, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 01, 2024	mukai takeo	sold (taxes)	-1,779	0.21	-8,475	cfo
Feb 06, 2024	sohn tom	sold (taxes)	-1,311	0.173	-7,582	svp, gen. counsel & secretary
Feb 01, 2024	sohn tom	sold (taxes)	-1,090	0.191	-5,709	svp, gen. counsel & secretary
Feb 01, 2024	mukai takeo	sold (taxes)	-547	0.191	-2,869	cfo
Jan 07, 2024	mathews kevin	sold (taxes)	-1,198	0.189	-6,342	svp, commercial
Jan 07, 2024	roman david	sold (taxes)	-4,552	0.189	-24,086	president & ceo
Sep 01, 2023	mukai takeo	sold (taxes)	-843	0.488	-1,729	cfo
Aug 05, 2023	sohn tom	sold (taxes)	-298	0.69	-433	svp, gen. counsel & secretary
Aug 05, 2023	mathews kevin	sold (taxes)	-92.46	0.69	-134	svp, commercial
Aug 02, 2023	mukai takeo	sold (taxes)	-	-	-501	cfo

Which funds bought or sold AFIB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	-721	9,752	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	sold off	-100	-2,300	-	-%
May 15, 2024	Royal Bank of Canada	reduced	-32.8	-	-	-%
May 15, 2024	DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	unchanged	-	-36,985	500,232	0.01%
May 15, 2024	ORBIMED ADVISORS LLC	unchanged	-	-36,812	497,897	0.01%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-22,947	-	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	new	-	14,759	14,759	-%
May 15, 2024	First Business Financial Services, Inc.	sold off	-100	-2,019	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	0.89	-145	2,231	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	reduced	-37.58	-66.00	94.00	-%

Are Funds Buying or Selling AFIB?

Are funds buying AFIB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AFIB

No. of Funds

Unveiling Acutus Medical, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Nov 13, 2023	flynn james e	5.54%	5,731,096	SC 13D/A
Feb 13, 2023	capital world investors	2.8%	797,523	SC 13G/A
Jul 05, 2022	flynn james e	5.72%	5,731,096	SC 13D/A
Apr 27, 2022	flynn james e	5.74%	3,841,587	SC 13D/A
Feb 14, 2022	advent life sciences llp	5.8%	1,617,149	SC 13G/A
Feb 11, 2022	kerrisdale advisers, llc	0%	0	SC 13G/A
Feb 11, 2022	capital world investors	5.7%	1,600,000	SC 13G
Nov 18, 2021	orbimed advisors llc	9.5%	2,648,386	SC 13D/A
Aug 31, 2021	orbimed advisors llc	7.7%	6,881,953	SC 13D/A
Aug 26, 2021	flynn james e	5.81%	3,841,587	SC 13D/A

Recent SEC filings of Acutus Medical, Inc.

View All Filings

Date Filed	Form Type	Document
May 17, 2024	SC 13G	Major Ownership Report
May 17, 2024	8-K	Current Report
May 16, 2024	25-NSE	25-NSE
May 09, 2024	8-K	Current Report
May 09, 2024	10-Q	Quarterly Report
May 03, 2024	8-K	Current Report
Apr 25, 2024	DEFA14A	DEFA14A
Apr 25, 2024	DEF 14A	DEF 14A
Apr 25, 2024	ARS	ARS
Apr 04, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Acutus Medical, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

Acutus Medical, Inc. News

Latest updates

Acutus Medical, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Revenue	-18.2%	3,625,000	4,431,500	5,238,000	5,289,000	4,170,000	3,907,000	3,644,000	4,076,000	3,681,000	4,362,000	4,601,000	4,709,000	3,591,000	2,574,000	3,173,000	1,134,000	1,583,000	1,114,500	646,000	734,000
Gross Profit	-100.5%	-30,000	5,614,000	-3,357,000	-2,774,000	-2,620,000	10,278,000	-3,307,000	-5,621,000	-3,260,000	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	101.8%	545,000	-30,072,000	9,579,000	14,397,000	14,687,000	-74,928,000	17,154,000	-20,549,000	35,370,000	34,262,000	31,690,000	32,009,000	31,424,000	30,580,000	29,435,000	20,599,000	19,183,000	-	31,810,000	14,609,000
S&GA Expenses	127.3%	3,337,000	-12,214,500	7,432,000	9,284,000	9,565,000	-17,892,000	9,679,000	14,143,000	14,385,000	15,865,000	15,805,000	15,601,000	16,252,000	15,164,000	15,833,000	9,125,000	10,235,000	-	7,978,000	6,927,000
R&D Expenses	100.0%	-	-14,229,500	4,795,000	6,799,000	6,117,000	-18,766,000	5,946,000	7,935,000	8,003,000	8,840,000	9,299,000	9,174,000	9,370,000	8,962,000	8,343,000	8,176,000	7,973,000	7,540,000	5,865,000	5,247,000
EBITDA Margin	240.1%	1.18	-0.84	6.58	6.53	14.19	11.34	-4.73	-4.92	-6.72	-6.15	-6.78	-7.72	-9.92	-	-	-	-	-	-	-
Interest Expenses	-4.3%	1,478,000	1,544,500	1,409,000	1,395,000	1,307,000	1,339,000	1,109,000	1,290,000	1,411,000	1,415,000	1,441,000	1,456,000	1,388,000	1,416,000	1,366,000	1,370,000	1,354,000	-	1,394,000	13,769,000
Income Taxes	100.0%	-	-12,000	75,000	-	-	15,000	-	-	-	-	-	-	-	23,000	-	-	-	-	-	-
Earnings Before Taxes	-105.7%	-2,055,000	35,965,000	-13,162,000	-18,346,000	-16,315,000	83,572,000	-20,425,000	5,718,000	-40,017,000	-31,264,000	-28,511,000	-28,727,000	-29,181,000	-29,379,000	-31,288,000	-23,193,000	-18,098,000	-	-	-
EBT Margin	120.3%	0.34	-1.66	5.83	5.59	12.93	9.52	-5.46	-5.63	-7.41	-6.82	-7.48	-8.44	-10.79	-	-	-	-	-	-	-
Net Income	95.2%	-1,620,000	-33,765,000	-13,237,000	-18,346,000	-16,315,000	15,108,000	-20,425,000	5,718,000	-40,017,000	-31,264,000	-28,511,000	-28,727,000	-29,181,000	-29,421,000	-31,288,000	-23,193,000	-18,098,000	-	-32,085,000	-30,345,000
Net Income Margin	18.0%	-9.35	-11.40	-5.35	-7.84	-3.92	-13.07	-5.46	-5.63	-7.41	-6.82	-7.49	-8.44	-10.80	-	-	-	-	-	-	-
Free Cashflow	-1.2%	-17,034,000	-16,838,000	-14,418,000	-15,334,000	-16,747,000	-14,619,000	-22,108,000	-23,730,000	-28,688,000	-25,968,000	-27,946,000	-25,775,000	-29,966,000	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																	(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	-22.8%	42.00	54.00	85.00	100	116	133	115	138	132	170	197	141	162	193	213	72.00	105
Current Assets	-25.6%	34.00	46.00	73.00	87.00	102	118	94.00	116	104	126	156	102	116	151	176	46.00	82.00
Cash Equivalents	-3.7%	18.00	19.00	24.00	23.00	23.00	26.00	32.00	51.00	12.00	24.00	59.00	7.00	9.00	25.00	58.00	24.00	10.00
Inventory	37.6%	6.00	4.00	16.00	16.00	15.00	2.00	15.00	15.00	18.00	16.00	15.00	15.00	14.00	13.00	11.00	12.00	8.00
Net PPE	2.3%	1.00	1.00	7.00	7.00	8.00	2.00	10.00	11.00	13.00	14.00	15.00	15.00	15.00	12.00	10.00	8.00	4.00
Goodwill	-	-	-	-	-	-	-	-	-	-	12.00	12.00	12.00	12.00	12.00	12.00	12.00	12.00
Liabilities	-16.7%	46.00	55.00	53.00	57.00	56.00	58.00	57.00	62.00	63.00	64.00	64.00	65.00	62.00	66.00	60.00	75.00	78.00
Current Liabilities	-47.9%	10.00	19.00	15.00	18.00	17.00	20.00	18.00	23.00	17.00	19.00	18.00	18.00	18.00	22.00	16.00	31.00	32.00
Long Term Debt	0.5%	33.00	33.00	35.00	35.00	35.00	34.00	34.00	34.00	41.00	40.00	40.00	40.00	39.00	39.00	39.00	39.00	38.00
LT Debt, Current	-2.4%	2.00	2.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	33.00	35.00	35.00	35.00	34.00	34.00	34.00	41.00	40.00	40.00	40.00	39.00	39.00	39.00	39.00	38.00
Shareholder's Equity	-357.3%	-4.02	-0.88	32.00	44.00	60.00	75.00	58.00	77.00	69.00	106	134	76.00	100	127	153	-	-
Retained Earnings	-0.3%	-601	-599	-566	-552	-534	-518	-533	-513	-518	-478	-447	-418	-390	-361	-331	-300	-259
Additional Paid-In Capital	-0.3%	598	600	599	598	596	594	592	590	588	585	581	495	490	487	484	36.00	33.00
Shares Outstanding	1.4%	30.00	29.00	29.00	29.00	29.00	29.00	28.00	28.00	28.00	28.00	29.00	28.00	28.00	-	-	-	-
Float	-	-	-	-	26.00	-	-	-	32.00	-	-	-	304	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																				(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2
Cashflow From Operations	6.0%	-16,929	-18,013	-14,008	-14,582	-16,515	-16,864	-21,353	-23,100	-27,600	-22,582	-27,200	-23,627	-26,273	-24,162	-26,277	-17,203	-17,558	-	-	-
Share Based Compensation	110.7%	202	-1,883	1,278	1,734	1,904	-4,097	1,884	2,581	3,032	3,491	3,577	3,776	2,910	2,831	6,374	1,157	1,741	-	812	803
Cashflow From Investing	-17.7%	9,230	11,220	16,949	15,137	15,249	12,218	3,365	73,169	15,999	-11,424	-3,532	21,850	12,172	-9,569	-106,905	20,933	31,717	-	-	-
Cashflow From Financing	91.5%	-42.00	-495	-1,935	-21.00	-213	485	-458	-11,601	-42.00	-514	82,232	229	-2,378	433	167,115	-531	-2,584	-	-	-
Buy Backs	100.0%	-	-275	12.00	46.00	217	49.00	17.00	45.00	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AFIB Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Comprehensive Income [Abstract]
Revenue	$ 3,625	$ 1,242
Cost of products sold	3,655	2,111
Gross loss	(30)	(869)
Operating (income) expenses:
Research and development	0	938
Selling, general and administrative	3,337	4,472
Change in fair value of contingent consideration	0	200
Gain on sale of business	(2,792)	(1,207)
Total operating expenses	545	4,403
Loss from operations	(575)	(5,272)
Other income (expense):
Change in fair value of warrant liability	(283)	1,446
Interest income	281	853
Interest expense	(1,478)	(1,307)
Total other (expense) income, net	(1,480)	992
Loss from continuing operations before income taxes	(2,055)	(4,280)
Income tax expense	0	0
Net loss from continuing operations	(2,055)	(4,280)
Discontinued operations:
Income (loss) from discontinued operations before taxes	445	(12,035)
Income tax expense - discontinued operations	(10)	0
Income (loss) from discontinued operations	435	(12,035)
Net loss	(1,620)	(16,315)
Other comprehensive income (loss)
Unrealized gain on marketable securities	0	12
Foreign currency translation adjustment	0	59
Comprehensive loss	$ (1,620)	$ (16,244)
Net (loss) earnings per share, basic and diluted
Net loss- continuing operations, basic (in dollars per share)	$ (0.07)	$ (0.15)
Net loss- continuing operations, diluted (in dollars per share)	(0.07)	(0.15)
Net income (loss)- discontinued operations, basic (in dollars per share)	0.01	(0.42)
Net income (loss)- discontinued operations, diluted (in dollars per share)	0.01	(0.42)
Net loss per common share, basic (in dollars per share)	(0.06)	(0.57)
Net loss per common share, diluted (in dollars per share)	$ (0.06)	$ (0.57)
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Weighted average number of common shares outstanding, basic (in shares)	29,693,926	28,764,444
Weighted average number of common shares outstanding, diluted (in shares)	29,693,926	28,764,444

AFIB Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 18,459	$ 19,170
Marketable securities, short-term	1,495	3,233
Restricted cash, short-term	0	7,030
Accounts receivable	7,750	11,353
Inventory	5,888	4,278
Prepaid expenses and other current assets	572	678
Current assets of discontinued operations	240	510
Total current assets	34,404	46,252
Noncurrent assets
Property and equipment, net	844	825
Right-of-use assets, net	3,011	3,189
Other assets	94	94
Noncurrent assets of discontinued operations	3,315	3,600
Total assets	41,668	53,960
Current liabilities:
Accounts payable	3,165	2,761
Accrued liabilities	2,063	2,887
Operating lease liabilities, short-term	835	718
Long-term debt, current portion	1,819	1,864
Warrant liability	692	409
Current liabilities of discontinued operations	1,300	10,303
Total current liabilities	9,874	18,942
Operating lease liabilities, long-term	3,009	3,243
Long-term debt	32,805	32,654
Total liabilities	45,688	54,839
Commitments and contingencies (Note 11)
Stockholders' deficit
Preferred stock, $0.001 par value; 5,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 5,000,000 shares of the preferred stock, designated as Series A Common Equivalent Preferred Stock, are issued and outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value; 260,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 29,715.962 and 29,313,667 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	30	29
Additional paid-in capital	598,413	599,935
Accumulated deficit	(601,597)	(599,977)
Accumulated other comprehensive loss	(866)	(866)
Total stockholders' deficit	(4,020)	(879)
Total liabilities and stockholders' deficit	$ 41,668	$ 53,960

About Acutus Medical, Inc.

Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact force ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. The company was incorporated in 2011 and is headquartered in Carlsbad, California.

CEO	Mr. David Harrison Roman
WEBSITE	acutusmedical.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	225

Acutus Medical, Inc. Frequently Asked Questions

What is the ticker symbol for Acutus Medical, Inc.? What does AFIB stand for in stocks?

AFIB is the stock ticker symbol of Acutus Medical, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Acutus Medical, Inc. (AFIB)?

As of Fri May 17 2024, market cap of Acutus Medical, Inc. is 1.78 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AFIB stock?

You can check AFIB's fair value in chart for subscribers.

What is the fair value of AFIB stock?

You can check AFIB's fair value in chart for subscribers. The fair value of Acutus Medical, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Acutus Medical, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AFIB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Acutus Medical, Inc. a good stock to buy?

The fair value guage provides a quick view whether AFIB is over valued or under valued. Whether Acutus Medical, Inc. is cheap or expensive depends on the assumptions which impact Acutus Medical, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AFIB.

What is Acutus Medical, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, AFIB's PE ratio (Price to Earnings) is -0.03 and Price to Sales (PS) ratio is 0.25. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AFIB PE ratio will change depending on the future growth rate expectations of investors.